148 related articles for article (PubMed ID: 12969149)
1. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.
Sweeney WE; Hamahira K; Sweeney J; Garcia-Gatrell M; Frost P; Avner ED
Kidney Int; 2003 Oct; 64(4):1310-9. PubMed ID: 12969149
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
Sweeney WE; Chen Y; Nakanishi K; Frost P; Avner ED
Kidney Int; 2000 Jan; 57(1):33-40. PubMed ID: 10620185
[TBL] [Abstract][Full Text] [Related]
3. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
Dell KM; Nemo R; Sweeney WE; Levin JI; Frost P; Avner ED
Kidney Int; 2001 Oct; 60(4):1240-8. PubMed ID: 11576338
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
[TBL] [Abstract][Full Text] [Related]
5. EGF-related growth factors in the pathogenesis of murine ARPKD.
MacRae Dell K; Nemo R; Sweeney WE; Avner ED
Kidney Int; 2004 Jun; 65(6):2018-29. PubMed ID: 15149315
[TBL] [Abstract][Full Text] [Related]
6. Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.
Nakanishi K; Gattone VH; Sweeney WE; Avner ED
Pediatr Nephrol; 2001 Jan; 16(1):45-50. PubMed ID: 11198603
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.
Nemo R; Murcia N; Dell KM
Pediatr Res; 2005 May; 57(5 Pt 1):732-7. PubMed ID: 15774823
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Folprecht G; Tabernero J; Köhne CH; Zacharchuk C; Paz-Ares L; Rojo F; Quinn S; Casado E; Salazar R; Abbas R; Lejeune C; Marimón I; Andreu J; Ubbelohde U; Cortes-Funes H; Baselga J
Clin Cancer Res; 2008 Jan; 14(1):215-23. PubMed ID: 18172273
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD.
Sweeney WE; Kusner L; Carlin CR; Chang S; Futey L; Cotton CU; Dell KM; Avner ED
Am J Physiol Cell Physiol; 2001 Nov; 281(5):C1695-705. PubMed ID: 11600434
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
11. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.
Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
Kidney Int; 2003 Nov; 64(5):1573-9. PubMed ID: 14531789
[TBL] [Abstract][Full Text] [Related]
12. Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice.
Ricker JL; Gattone VH; Calvet JP; Rankin CA
J Am Soc Nephrol; 2000 Oct; 11(10):1837-1847. PubMed ID: 11004214
[TBL] [Abstract][Full Text] [Related]
13. Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease.
Gattone VH; Ricker JL; Trambaugh CM; Klein RM
Kidney Int; 2002 Nov; 62(5):1560-9. PubMed ID: 12371956
[TBL] [Abstract][Full Text] [Related]
14. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.
Sweeney WE; Frost P; Avner ED
World J Nephrol; 2017 Jul; 6(4):188-200. PubMed ID: 28729967
[TBL] [Abstract][Full Text] [Related]
15. Src inhibition ameliorates polycystic kidney disease.
Sweeney WE; von Vigier RO; Frost P; Avner ED
J Am Soc Nephrol; 2008 Jul; 19(7):1331-41. PubMed ID: 18385429
[TBL] [Abstract][Full Text] [Related]
16. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
Gattone VH; Maser RL; Tian C; Rosenberg JM; Branden MG
Dev Genet; 1999; 24(3-4):309-18. PubMed ID: 10322639
[TBL] [Abstract][Full Text] [Related]
17. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.
Ricker JL; Mata JE; Iversen PL; Gattone VH
Kidney Int; 2002 Jan; 61(1 Suppl):S125-31. PubMed ID: 11841626
[TBL] [Abstract][Full Text] [Related]
18. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease.
Sweeney WE; Avner ED
Am J Physiol; 1998 Sep; 275(3):F387-94. PubMed ID: 9729511
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor ameliorates autosomal recessive polycystic kidney disease in mice.
Gattone VH; Lowden DA; Cowley BD
Dev Biol; 1995 Jun; 169(2):504-10. PubMed ID: 7781894
[TBL] [Abstract][Full Text] [Related]
20. Decreased amiloride-sensitive Na+ absorption in collecting duct principal cells isolated from BPK ARPKD mice.
Veizis EI; Carlin CR; Cotton CU
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F244-54. PubMed ID: 14559716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
